Table 1.
Participant characteristicsa
| Donor Type | |||
|---|---|---|---|
| Related | Unrelated | All participants | |
| Total number | 24 | 78 | 102 |
| Sex, female/male (% female) | 9/15 (38%) | 28/50 (36%) | 37/65 (36%) |
| Actual body weight (kg) | 80 (50 – 119) | 83 (45 – 142) | 82 (45 – 142) |
| HCT-CI[40] | |||
| 0 | 1 (4%) | 8 (10%) | 9 (9%) |
| 1–2 | 3 (13%) | 17 (22%) | 20 (20%) |
| 3–4 | 11 (46%) | 30 (38%) | 41 (40%) |
| ≥5 | 9 (38%) | 23 (29%) | 32 (32%) |
| Recipients’ ages, years | 59 (20 – 69) | 62 (28 – 75) | 62 (20 – 75) |
| CMV positive recipient or donor | 16 (67%) | 51 (65%) | 67 (66%) |
| Kahl Disease risk[27] | |||
| Low | 4 (17%) | 29 (37%) | 33 (32%) |
| Standard | 16 (67%) | 33 (42%) | 49 (48%) |
| High | 4 (17%) | 16 (21%) | 20 (20%) |
| Diagnosis | |||
| Non-Hodgkin lymphoma | 7 (29%) | 27 (35%) | 34 (33%) |
| Chronic lymphocytic leukemia | 8 (33%) | 14 (18%) | 22 (22%) |
| Acute myelogenous leukemia | 4 (17%) | 11 (14%) | 15 (15%) |
| Myelodysplastic syndrome | 1 (4%) | 9 (12%) | 10 (10%) |
| Multiple myeloma | 1 (4%) | 8 (10%) | 9 (9%) |
| Acute lymphocytic leukemia | 1 (4%) | 3 (4%) | 4 (4%) |
| Myelofibrosis / Myeloproliferative disorder | 0 | 3 (4%) | 3 (3%) |
| Aplastic anemia | 0 | 2 (3%) | 2 (2%) |
| Hodgkin disease | 2 (8%) | 0 | 2 (2%) |
| Paroxysmal nocturnal hemoglobinuria | 0 | 1 (1%) | 1 (1%) |
| Female donor to male recipient | 10 (42%) | 19 (24%) | 29 (28%) |
| Donors’ ages, years | 55 (23 – 73) | 31 (20 – 58) | 35 (20 – 73) |
| HLA-mismatched graft | 1 (4%) | 2 (3%) | 3 (3%) |
| Conditioning regimen | |||
| 2Gy TBI + FLU ± auto | 11 (46%) | 38 (49%) | 49 (48%) |
| 2Gy TBI + FLU + rituximab ± autob | 11 (46%) | 20 (26%) | 31 (30%) |
| 3Gy TBI + FLU ± rituximabb | 2 (8%) | 13 (17%) | 15 (15%) |
| 4–4.5 Gy TBI + FLU | 0 | 7 (9%) | 7 (7%) |
| Post-grafting immunosuppression | |||
| MMF Q8h | 1 (4%) | 78 (100%) | 79 (77%) |
| MMF Q12h | 23 (96%) | 0 | 23 (23%) |
| Cyclosporine+MMF±sirolimusc | 14 (58%) | 54 (69%) | 68 (67%) |
| Tacrolimus+MMF±sirolimusd | 10 (42%) | 24 (31%) | 34 (33%) |
a
Data shown as median (range) or as number (%).
b
Rituximab given on days −3, +10, +24, and +38 relative to transplant;
c
Ten participants received cyclosporine + sirolimus, one with a matched donor and nine with unrelated donors;
d
Five participants received tacrolimus + sirolimus, all with unrelated donors.
Abbreviations: auto: autologous transplant; CMV: cytomegalovirus; FLU: fludarabine monophosphate; HCT-CI: HCT comorbidity index; HLA: human leukocyte antigen; MMF: mycophenolate mofetil; TBI: total body irradiation.